×

Agilent raises 2026 profit forecast on strong demand for lab tools

By Thomson Reuters May 27, 2026 | 3:09 PM

By Siddhi Mahatole and Bageshri Banerjee

May 27 (Reuters) – Agilent Technologies raised its 2026 adjusted profit forecast on Wednesday, anticipating strong demand for its medical tools and equipment ​used in lab research and diagnostic services.

Shares of the ‌life sciences firm rose more than 10% in after-hours trading.

U.S. life sciences and lab-equipment makers, which had struggled with uneven demand and tight biotech funding in recent years, are now seeing gradual improvements.

The company now expects ‌annual ​adjusted per-share profit of $6 to $6.10, compared ⁠with its prior forecast ⁠of $5.90 to $6.04 apiece, an increase of 8 cents at the midpoint. Analysts’ average expectation is $5.97 per share, according to data compiled by LSEG.

CEO Padraig McDonnell said in a call with analysts ​that Agilent has factored additional assumptions into its full-year forecast, including rising cost pressures.

The company expects higher costs from ⁠the Middle East conflict and strong ⁠demand for memory chips, which has tightened supply ​chains and increased component prices, but said efficiencies from its cost-cutting ​program should help offset these pressures in the second ‌half of the year.

It also said inflationary pressures linked to the conflict could weigh on capital spending, though it expects a strong recovery to accelerate, potentially sooner than anticipated.

Agilent forecasts third-quarter ⁠adjusted profit in the range of $1.48 to $1.50 per share, compared with analysts’ estimates of $1.50 per share.

The company reported an adjusted profit of $1.49 ⁠per share for the second ‌quarter, above estimates of $1.41 per share.

Its revenue ⁠came in at $1.83 billion for the quarter ended ​April ‌30, compared with the consensus estimate of $1.80 ​billion.

Quarterly sales ⁠in its life sciences and diagnostics segment were at $732 million, beating analysts’ expectations of $694.7 million.

Revenue from its CrossLab unit, which offers products and services for laboratory management, rose 6% to $759 million in the quarter.

(Reporting by Siddhi Mahatole and Bageshri Banerjee in Bengaluru; editing ​by Alan Barona)